Dallas, Texas 03/03/2014 (FINANCIALSTRENDS) – Cell Therapeutics Inc(NASDAQ:CTIC) is the US based biotechnology company which has been a long time player on the pharma market, with innovative therapies and stock solutions. The company operates on multiple lines- development, acquisition as well as commercialization of the products it develops for treating cancers. The idea is to extend the development and acquisition processes as well as adopting in-licensing solutions aimed at bringing new and effective solutions for one of the most harmful and fatal diseases that mankind has yet come to see-Cancer.
Cell Therapeutics Inc(NASDAQ:CTIC) concentrates on developing solutions which are new, but remain less toxic. On the other hand, the company has always been in the process of finding effective ways to overcome cancer.
Pixurvri receives NICE nod
Cell Therapeutics Inc(NASDAQ:CTIC) in the last week of February, 2014 has received the final recommendation for the use of its drug by NICE, the regulatory body in UK. Though the immediate control is on the cost of the drug and the health benefits, NICE has allowed the use of Cell Therapeutics, Inc. (NASDAQ:CTIC)Pixuvri. This drug is being used to treat a type of cancer which is more famous as the B-cell non-Hodgkin Lymphoma.
Cell Therapeutics Inc(NASDAQ:CTIC) will now look towards the National Health Service to explore and this type of treatment on the current patients coming to them. The company expressed its wish that doctors would now view this drug as the solution which will help and bring relief to those suffering from this disease.
Cell Therapeutics Inc(NASDAQ:CTIC) will look forward to bring out this drug in the approved regions of England as well as Wales by the spring of this year. As news of this approval hit the markets, prices of this drug maker were found to have gained market advantage at the time of opening of the trading day.